2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

European Heart Journal, Journal Year: 2022, Volume and Issue: 43(41), P. 4229 - 4361

Published: Aug. 26, 2022

65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic

Language: Английский

---

Immune Checkpoint Inhibitors in Cancer Therapy

Current Oncology, Journal Year: 2022, Volume and Issue: 29(5), P. 3044 - 3060

Published: April 24, 2022

The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these have been utilized successfully patients with metastatic melanoma, renal cell carcinoma, head neck cancers non-small lung cancer. US FDA has approved three different categories inhibitors (ICIs) PD-1 (Nivolumab, Pembrolizumab, Cemiplimab), PDL-1 (Atezolimumab, Durvalumab Avelumab), inhibitor (Ipilimumab). Unfortunately, not all respond favourably to drugs, highlighting role biomarkers Tumour mutation burden (TMB), expression, microbiome, hypoxia, interferon-γ, ECM predicting responses ICIs-based current study aims review literature updates on ICIs therapy.

Language: Английский

---

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Aug. 28, 2023

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-L1, novel LAG-3 drugs have also been approved clinical application. With the widespread use of drug, we must deeply analyze dilemma agents seek a breakthrough treatment prospect. Over past decades, these demonstrated dramatic efficacy, especially patients with melanoma non-small cell lung cancer (NSCLC). Nonetheless, field broad concept solid tumours, non-specific indications, inseparable immune response side effects, unconfirmed progressive disease, complex regulatory networks resistance are four barriers that limit its Fortunately, successful trials ICB combination therapies, advent era oncolytic virus gene editing, technical mRNA vaccines nano-delivery systems made remarkable breakthroughs currently. In this review, enumerate mechanisms each checkpoint targets, associations between tumour mutation burden, key or signalling pathways, specific evidence efficacy classical targets new among different types put forward dialectical thoughts on drug safety. Finally, discuss importance accurate triage based recent advances predictive biomarkers diagnostic testing techniques.

Language: Английский

---

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

European Heart Journal - Cardiovascular Imaging, Journal Year: 2022, Volume and Issue: 23(10), P. e333 - e465

Published: Aug. 26, 2022

Language: Английский

---

Emerging Therapies for Hepatocellular Carcinoma (HCC)

Cancers, Journal Year: 2022, Volume and Issue: 14(11), P. 2798 - 2798

Published: June 4, 2022

Hepatocellular carcinoma (HCC) arises from hepatocytes and accounts for 90% of primary liver cancer. According to Global Cancer Incidence, Mortality Prevalence (GLOBOCAN) 2020, globally HCC is the sixth most common cancer third cause cancer-related deaths. Reasons prognosis remaining dismal are that asymptomatic in its early stages, leading late diagnosis, it markedly resistant conventional chemo- radiotherapy. Liver transplantation treatment choice while surgical resection, radiofrequency ablation (RFA) trans arterial chemoembolization (TACE) Food Drug Administration (FDA)-approved treatments advanced HCC. Additional first line therapy includes broad-spectrum tyrosine kinase inhibitors (TKIs), such as sorafenib lenvatinib, well a combination immunotherapy anti-angiogenesis therapy, namely atezolizumab bevacizumab. However, these strategies provide nominal extension survival curve, broad spectrum toxic side effects, patients eventually develop resistance. Some mutations HCC, telomerase reverse transcriptase (

Language: Английский

---

RNA modifications: importance in immune cell biology and related diseases

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Sept. 22, 2022

RNA modifications have become hot topics recently. By influencing processes, including generation, transportation, function, and metabolization, they act as critical regulators of cell biology. The immune abnormality in human diseases is also a research focus progressing rapidly these years. Studies demonstrated that participate the multiple biological processes cells, development, differentiation, activation, migration, polarization, thereby modulating responses are involved some related diseases. In this review, we present existing knowledge functions underlying mechanisms modifications, N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N7-methylguanosine (m7G), N4-acetylcytosine (ac4C), pseudouridine (Ψ), uridylation, adenosine-to-inosine (A-to-I) editing, summarize their roles Via regulating can pathogenesis diseases, such cancers, infection, inflammatory autoimmune We further highlight challenges future directions based on knowledge. All all, review will provide helpful well novel ideas for researchers area.

Language: Английский

---

Emerging evidence for adapting radiotherapy to immunotherapy

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(8), P. 543 - 557

Published: June 6, 2023

Language: Английский

---

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: Oct. 8, 2022

Abstract The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation supervision. Over the past 31 years, 1050 drugs (excluding vaccines, cell-based therapies, gene therapy products) have approved as new molecular entities (NMEs) or biologics license applications (BLAs). A total of 228 these were identified cancer therapeutics cancer-related drugs, 120 them classified therapeutic for solid tumors according to their initial indications. These evolved from small molecules with broad-spectrum antitumor properties early stage monoclonal antibodies (mAbs) antibody‒drug conjugates (ADCs) more precise targeting effect during most recent decade. extended indications other malignancies, constituting treatment system monotherapy combined therapy. However, available targets are still mainly limited receptor tyrosine kinases (RTKs), restricting development drugs. In this review, summarized indications, characteristics, functions. Additionally, RTK-targeted therapies immune checkpoint-based immunotherapies also discussed. Our analysis existing challenges potential opportunities may advance tumor future.

Language: Английский

---

Cancer treatments: Past, present, and future

Cancer Genetics, Journal Year: 2024, Volume and Issue: 286-287, P. 18 - 24

Published: June 17, 2024

Language: Английский

---

Immune Checkpoint Inhibitor Therapy in Oncology

JACC CardioOncology, Journal Year: 2022, Volume and Issue: 4(5), P. 579 - 597

Published: Dec. 1, 2022

Language: Английский

---